HR+HER2− breast cancers with growth factor receptor–mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells

HR+HER2− breast cancers with growth factor receptor–mediated EMT have a poor prognosis and lapatinib downregulates EMT in MCF-7 cells

Despite an overall good prognosis, a significant proportion of patients with hormone receptor positive human epidermal growth factor receptor 2 negative breast cancers develop distant metastases. The metastatic potential of epithelial cells is known to be regulated by tumor–stromal interaction and m...

Full description

Bibliographic Details
Main Authors: Krisha Desai, Radhika Aiyappa, Jyothi S Prabhu, Madhumathy G Nair, Patrick Varun Lawrence, Aruna Korlimarla, Anupama CE, Annie Alexander, Rohini S Kaluve, Suraj Manjunath, Marjorrie Correa, BS Srinath, Shekhar Patil, Anjali Kalamdani, MSN Prasad, TS Sridhar
Format: Article
Language:English
Published: IOS Press 2017-03-01
Series:Tumor Biology
Online Access:https://doi.org/10.1177/1010428317695028

Internet

https://doi.org/10.1177/1010428317695028

Similar Items